4SC Overview

  • Founded
  • 1997
Founded
  • Status
  • Public
  • Employees
  • 48
Employees
  • Stock Symbol
  • VSC
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $1.78
  • (As of Friday Closing)

4SC General Information

Description

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. The company's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: Resminostat and Domatinostat.

Contact Information

Website
www.4sc.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
ETR
Primary Office
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • Germany
+49 089 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

4SC Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.78 $1.67 $1.61 - $2.80 $84.7M 50.6M 18.7K -$0.47

4SC Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 59,409 59,409 91,462 58,179
Revenue 2,567 2,567 2,458 4,924
EBITDA (20,453) (20,453) (14,229) (19,734)
Net Income (21,645) (21,645) (15,630) (20,839)
Total Assets 52,227 52,227 59,316 35,754
Total Debt 1,921 1,921 2,026 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

4SC Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 4SC‘s full profile, request access.

Request a free trial

4SC Executive Team (8)

Name Title Board Seat Contact Info
Jason Loveridge Ph.D Chief Executive Officer & Chairman of the Management Board
Frank Hermann MD Chief Development Officer
Susanne Danhauser-Riedl MD Chief Medical Officer
You’re viewing 3 of 8 executive team members. Get the full list »

4SC Board Members (10)

Name Representing Role Since
Clemens Doppler Ph.D HeidelbergCapital Board Member 000 0000
Daniel Vitt Ph.D Self Board Member & Founder 000 0000
Helga Rubsamen-Schaeff Ph.D 4SC Member of the Supervisory Board 000 0000
Helmut Jeggle Self Supervisory Board Member 000 0000
Irina Antonijevic Ph.D Self Spervisory Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

4SC Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

4SC Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 4SC‘s full profile, request access.

Request a free trial

4SC Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000 02-Nov-2015 0000 00000 00.000 Drug Discovery
Nexigen 26-May-2008 Corporate Drug Discovery 000000 0000 00.0
To view 4SC’s complete investments history, request access »

4SC Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000 02-Nov-2015 0000 00000 00.000 Completed
  • 4 buyers
Nexigen 26-May-2008 Corporate Completed
To view 4SC’s complete exits history, request access »